Insulet Q2 2026 Preview: Can 33% Growth Quiet the Expectations Trap?

Q1's beat raised the bar for Insulet's next report

Insulet entered this quarter with momentum after a very strong first-quarter print. That helps the story, but it also makes the trade more difficult.

Why Q1 made expectations harder to clear

Insulet reported EPS of $1.42 versus $1.19 expected, while revenue reached $761.70 million against roughly $729.89 million expected. That kind of result does two things at once: it validates the growth narrative and pushes analysts higher.

After a quarter like that, investors usually stop asking whether the business is healthy. They start asking whether the pace can continue. That is the expectations trap: recency bias makes the last standout quarter the benchmark, so a routine good quarter may not be enough.

The timing tightens that pressure. Insulet reports August 5 before the market opens, with the conference call at 8:00 AM ET. The market will be judging not just the headline numbers, but also whether management can defend the forward narrative.

The bull case rests on Insulet's AID leadership and TAM expansion

The main bullish argument is no longer about near-term growth alone. It is about whether Insulet still looks underpenetrated relative to the automated insulin delivery market it helps define.

Omnipod 5 has driven outsized category growth

Insulet says it delivered 66% of AID market growth over the past five years, while the core business grew at a 25% CAGR from 2021 to 2025, reaching about $2.7 billion of 2025 revenue. That is the kind of track record that can support a premium valuation because it points to category leadership, not just solid execution.

Recent product-share data also supports that view. In Q4, Omnipod 5 accounted for more than 90% of new customer starts, and Insulet had more than 100,000 Omnipod 5 customers versus an estimated 360,000-person user base. That leaves meaningful room if adoption keeps spreading.

TAM expansion is the longer-term argument

Management's own estimates suggest the opportunity extends well beyond today's footprint. Insulet estimates a current TAM of about 8 million people with diabetes, or roughly $6 billion in total market value, with the market projected at about $9 billion by 2028. A longer-term roadmap includes expansion to roughly 17 million people with diabetes through type 1 diabetes markets outside the US, type 2 diabetes for basal-only treatment in the US, and broader type 1 coverage in Asia.

For this earnings preview, that expansion matters less than proof that the current engine is still running. Bulls need evidence that customer growth, switches, and payers are moving at a pace that justifies looking ahead to that larger TAM.

What could pressure the premium multiple

The real stress test is not whether Insulet can grow again. It is whether management can keep the market paying for TAM while the business keeps turning that opportunity into repeatable revenue. After Q1 revenue of $761.70 million and a 33.9% year-over-year increase, investors may be quick to read small wobbles as bigger problems.

Competition and conversion are the watchpoints

The clearest near-term risk is not TAM itself, but whether Insulet can keep winning switches as the category gets more competitive. Management has already flagged competitive pressures from other diabetes technology providers, and earlier international commentary pointed to ongoing impact of AID competition even during strong growth periods. That does not invalidate the story, but it does mean execution matters more as the market gets noisier.

There is also a timing issue. Insulet's roadmap includes Omnipod 6 expected to be launched in 2027 and a fully-closed loop system for type 2 diabetes expected in 2028. If near-term momentum slips, the market may become less willing to discount a distant endpoint and more focused on present execution.

What to watch on the call

A useful framework is to treat this as an expectation-management report, not just a binary beat-or-miss event.

• What would support the trend: management holds near current Q2 consensus EPS of $1.19, keeps demand commentary constructive, and points to healthy adoption rates of the Omnipod 5 system.
• What would raise concern: a quarter that merely clears the floor, paired with more defensive language on guidance after a 33.9% Q1 revenue jump.
• What matters most on the call: commentary on new customer additions, competitive switching, and whether competitive pressure is starting to outweigh Omnipod 5 adoption momentum.

The real question into Insulet Q2 earnings

Can Insulet show that Q1 was the start of a higher base rather than a one-off outlier? After Q1 EPS of $1.42 and revenue of $761.70 million, that is the question the August 5 report is really designed to answer.